Kura Oncology Logo
Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer
25 août 2020 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Reports Second Quarter 2020 Financial Results
06 août 2020 16h05 HE | Kura Oncology, Inc.
– Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH – – Continued progress in registration-directed trial of tipifarnib in HRAS mutant HNSCC – – Opportunity to...
Kura Oncology Logo
Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference
04 août 2020 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Logo
Kura Oncology to Report Second Quarter 2020 Financial Results
30 juil. 2020 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Logo
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
16 sept. 2019 07h30 HE | Kura Oncology, Inc.
– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 ...
Kura Oncology Logo
Kura Oncology to Participate in Two Upcoming Investor Conferences
06 mars 2019 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
05 mars 2019 07h30 HE | Kura Oncology, Inc.
– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction – – Robust anti-tumor activity observed in mixed lineage leukemias rearranged and oncogenic driver mutations in...
Kura Oncology Logo
Kura Oncology to Present at JMP Securities Life Sciences Conference
14 juin 2018 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology to Report First Quarter 2018 Financial Results
01 mai 2018 07h30 HE | Kura Oncology, Inc.
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Logo
Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML
28 oct. 2017 12h30 HE | Kura Oncology, Inc.
NPM1 and DNMT3A-mutants comprise approximately 45% of AML patientsMenin-MLL complex appears to be central node in epigenetic dysregulation giving rise to AML SAN DIEGO, Oct. 28, 2017 (GLOBE...